Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) insider David Hochman purchased 10,000 shares of the firm's stock in a transaction that occurred on Friday, March 13th. The shares were acquired at an average cost of $4.29 per share, with a total value of $42,900.00. Following the completion of the purchase, the insider directly owned 1,086,467 shares in the company, valued at $4,660,943.43. The trade was a 0.93% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Orchestra BioMed Stock Performance
Shares of Orchestra BioMed stock opened at $4.55 on Tuesday. The stock's fifty day moving average is $4.19 and its two-hundred day moving average is $3.87. The company has a market capitalization of $266.27 million, a PE ratio of -4.03 and a beta of 0.56. The company has a quick ratio of 6.43, a current ratio of 6.45 and a debt-to-equity ratio of 0.27. Orchestra BioMed Holdings, Inc. has a 52 week low of $2.20 and a 52 week high of $5.42.
Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last released its earnings results on Thursday, March 12th. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.64. The business had revenue of $30.92 million for the quarter, compared to analyst estimates of $0.93 million. Orchestra BioMed had a negative return on equity of 184.17% and a negative net margin of 157.40%. As a group, analysts expect that Orchestra BioMed Holdings, Inc. will post -1.66 earnings per share for the current year.
Analyst Ratings Changes
A number of brokerages recently weighed in on OBIO. Chardan Capital reiterated a "buy" rating and set a $20.00 price objective on shares of Orchestra BioMed in a report on Thursday, March 12th. Wall Street Zen upgraded shares of Orchestra BioMed from a "strong sell" rating to a "hold" rating in a research note on Saturday. Barclays raised their target price on shares of Orchestra BioMed from $11.00 to $12.00 and gave the stock an "overweight" rating in a research report on Friday, January 9th. Finally, TD Cowen assumed coverage on Orchestra BioMed in a report on Wednesday, December 10th. They issued a "buy" rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $13.80.
View Our Latest Stock Analysis on OBIO
Institutional Investors Weigh In On Orchestra BioMed
A number of institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC raised its holdings in Orchestra BioMed by 9.2% in the third quarter. Citadel Advisors LLC now owns 54,002 shares of the company's stock worth $134,000 after purchasing an additional 4,561 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Orchestra BioMed by 35.7% during the second quarter. Bank of America Corp DE now owns 21,577 shares of the company's stock valued at $58,000 after buying an additional 5,678 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Orchestra BioMed in the 4th quarter valued at about $38,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of Orchestra BioMed in the 2nd quarter valued at about $31,000. Finally, Virtu Financial LLC purchased a new position in shares of Orchestra BioMed in the 4th quarter worth approximately $57,000. Institutional investors own 53.20% of the company's stock.
Orchestra BioMed Company Profile
(
Get Free Report)
Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.
Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
